Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
83.6M
-
Shares change
-
+14.6M
-
Total reported value, excl. options
-
$436M
-
Value change
-
+$74.6M
-
Put/Call ratio
-
3.88
-
Number of buys
-
63
-
Number of sells
-
-42
-
Price
-
$5.24
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q3 2017
147 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q3 2017.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 83.6M shares
of 210M outstanding shares and own 39.86% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (14M shares), RA CAPITAL MANAGEMENT, LLC (6.98M shares), BlackRock Inc. (6.62M shares), VANGUARD GROUP INC (6.01M shares), DEERFIELD MANAGEMENT CO (4.98M shares), JANUS HENDERSON GROUP PLC (4.53M shares), MILLENNIUM MANAGEMENT LLC (3.76M shares), RTW INVESTMENTS, LP (3.32M shares), VHCP Management II, LLC (3.17M shares), and FMR LLC (3.12M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.